Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vericiguat's Effects on Reverse Remodeling Indices: Pathophysiologic Approach to Treatment of Heart Failure With Reduced Ejection Fraction

NCT07405944 is registered in ClinicalTrials.gov with University Medical Centre Ljubljana as lead sponsor.

NCT NCT07405944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07405944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vericiguat's Effects on Reverse Remodeling Indices: Pathophysiologic Approach to Treatment of Heart Failure With Reduced Ejection Fraction
Lead sponsor
University Medical Centre Ljubljana
Phase
Phase 4
Overall status
Recruiting
Start date
November 1, 2025
Completion date
December 31, 2027
Enrollment
70 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure, heart failure with reduced ejection fraction (hfref)